Pentoxifylline and severe acute respiratory syndrome (SARS): A drug to be considered

Medical Science Monitor

Volumn 9, Issue 6, 2003, Pages

  Bermejo Martín, Jesús Fco ^a   Jiménez, José Luis ^a   Muńoz Fernández, M Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antiviral; Bronchodilation; Immunomodulation; Inflammation; Pentoxifylline; SARS

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISONE; RIBAVIRIN; ROLIPRAM;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CORONAVIRUS; CYTOKINE RELEASE; DOWN REGULATION; DRUG ABSORPTION; DRUG COST; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG TRANSFORMATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIASIS; LUNG ALVEOLITIS; LUNG ALVEOLUS; LUNG INFECTION; MACROPHAGE; NAUSEA; NONHUMAN; PATHOGENESIS; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STOMACH ACID SECRETION; STOMACH DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VERTIGO; VIRUS PNEUMONIA; VOMITING;

ANTIVIRAL AGENTS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PENTOXIFYLLINE; PNEUMOCYSTIS INFECTIONS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VASODILATOR AGENTS;

EID: 0037830323     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nicholls JM, Poon LLM, Lee CK et al: Lung pathology of fatal severe acute respiratory syndrome. The Lancet 2003; 36; 9370. Available from URL http://image.thelancet.com/extras/03art4347web.pdf
2. Amvros'eva TV, Votiakov VI, Andreeva OT et al: New properties of trental as an inhibitor of viral activity with a wide range of activity. [Article in Russian]. Vopr Virusol. 1993; 38: 230-3
3. Vasil'ev VS, Pron'ko NV: Use of trental in combined treatment of viral hepatitis. [Article in Russian]. Klin Med, 1990; 68(3): 68-70
4. Navarro J, Punzon MC, Pizarro A et al: Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS, 1996; 10(5): 469-75
5. Navarro, J, Punzon MC, Jimenez JL et al: Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type I replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol. 1998; 72: 4712-20
6. Biswas DK, Dezube BJ, Ahlers CM & Pardee AB: Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr, 1993; 6(7): 778-86
7. Clerici M, Piconi S, Balotta C et al: Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis, 1997; 17: 1210-5
8. Staak K, Prosch S, Stein J et al: Pentoxifylline promotes replication of human cytomegalovirus ill vivo and in vitro. Blood, 1997; 89: 3682-90
9. Shirabe S, Nakamura T, Tsujino A et al: Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci, 1997; 151(1): 97-101
10. Alarcón-Guzmán T, Alarcón-Avilés T: Treatment of tropical spastic paraparesis with Pentoxifylline: pilot study. [Article in Spanish]. Avalaible from URL: http://www.medicosecuador.com/revecautneurol/vol11_n1-2_2002/tratamiento_de_ la.htm
11. Fujimoto T, Nakamura T, Furuya T et al: Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type P cytokine levels in patients with human T-lymphotropic virus type 1-associated myelopathy. K. Intern Med, 1999; 38(9): 717-21
12. Entzian P, Bitter-Suermann S, Burdon D et al: Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? Allergy, 1998; 53(8): 749-54
13. Kuznetsova VK, Zhdanov VF, Yakovleva NG & Kuzubova NA: Dynamics of airflow limitation in bronchial asthmatic patients after trental therapy. Pulmonology, 1997; 7: Available from URL http://www.pulmonology.ru/sum-97-4.htm
14. Vassallo R, Standing JE & Andrew HL: Isolated Pneumocystis carinii Cell Wall Glucan Provokes Lower Respiratory Tract Inflammatory Responses. The J of Immunology, 2000; 164: 3755-3763
15. Entzian P, Gerlach C, Gerdes J et al: Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis. [Article in German]. Pneumologie 1997; 51(4): 375-80
16. Ardizzoia A, Lissoni P, Tancini G et al: Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study. Support Care Cancer, 1993; 1(6): 313-3
17. Korber M, Kamp S, Kothe H et al: Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis. [Article in German]. Immun Infekt, 1995; 23(3): 107-10
18. Balibrea JL, Arias-Diaz J, Garcia C, Vara E: Effect of pentoxifylline and somatostatin on tumor necrosis factor production by human pulmonary macrophages. Circ Shock, 1994; 43(2): 51-6
19. Lessa HA, Machado P, Lima F et al: Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg, 2000; 65(9): 87-9
20. Giembycz MA: Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis, 2002; 57: 48-64
21. Williams BRG, Sen GC: A Viral On/Off Switch for Interferon. Science, 2003; 300: 1100-1101
22. Vazquez Garcia MJ, Vargas Camano ME, Olalde Carmona R: Use of pentoxifylline in pediatric patients with grade IV (OMS) lupus nephropathy who have received multiple treatments. [Article in Spanish]. Rev Alerg Mex, 2000; 47(3): 109-14
23. Streppel M, Wittekindt C, von Wedel H et al: Progressive hearing loss in hearing impaired children: immediate results of antiphlogistic-rheologic infusion therapy. Int J Pediatr Otorhinolaryngol, 2001; 57(2): 129-36